|
RIA: Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial. |
|
|
Consulting or Advisory Role - Amgen; SERVIER |
Research Funding - Amgen; Sanofi |
Travel, Accommodations, Expenses - Amgen; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca (I); Boehringer Ingelheim (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CELGENE (I); IPSEN; Lilly (I); MERCK; Merck (I); MSD; MSD (I); Novartis; Novartis (I); PFIZER; Pfizer (I); ROCHE; Roche (I); SERVIER |
Consulting or Advisory Role - AstraZeneca (I); Boehringer Ingelheim (I); Bristol-Myers Squibb (I); IPSEN; Lilly (I); Merck Sharp & Dohme (I); MSD; Novartis (I); Pfizer (I); Roche (I) |
Research Funding - PFIZER |
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim (I); Ipsen; Lilly (I); Merck; Novartis; Pfizer; Pfizer (I); Roche; Roche (I); Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Merck; Roche |
Travel, Accommodations, Expenses - Merck; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Merck; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Merck; Roche; Sanofi |
Speakers' Bureau - Amgen; Merck; Roche; Sanofi |
Research Funding - Amgen; Merck; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |